Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis - Takeaways - MDSpire

Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

  • By

  • Renzhu Liu

  • Lu Xiao

  • Qingzi Yan

  • Xiang Liu

  • February 2, 2026

  • 0 min

Share

  • 1

    Ticagrelor is a P2Y12 inhibitor that provides rapid platelet inhibition, reducing cardiovascular mortality in acute coronary syndromes.

  • 2

    The drug's unique mechanism allows it to function without metabolic activation, making it effective regardless of food intake.

  • 3

    Ticagrelor's inhibition of the equilibrative nucleoside transporter 1 elevates plasma adenosine levels, contributing to its adverse effects.

  • 4

    The VigiAccess database is utilized to analyze adverse drug reactions associated with ticagrelor, highlighting the need for ongoing safety monitoring.

  • 5

    Reported adverse events include slow arrhythmia and ventricular cardiac arrest, necessitating careful patient monitoring during ticagrelor therapy.

Original Source(s)

Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

  • by Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu

  • February 2, 2026

Related Content

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Vericiguat's Effects on Acute Coronary Syndrome Patients with Diminished Ejection Fraction: Insights from the EVE-ACSrEF Trial